Welcome to our dedicated page for MESA LABORATORIES /CO/ SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESA LABORATORIES /CO/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESA LABORATORIES /CO/'s regulatory disclosures and financial reporting.
Kadia Siddhartha reported acquisition or exercise transactions in this Form 4 filing.
Mesa Laboratories reported that President and CEO Siddhartha Kadia received a grant of 34,807 Restricted Stock Units (RSUs) linked to the company’s common stock. Each RSU represents a contingent right to receive one share of common stock.
The RSUs vest in thirds, with 1/3 of the award vesting on each anniversary date, aligning the CEO’s compensation with longer-term company performance. Following this grant, the filing shows 34,807 RSUs held directly by the CEO, and no remaining derivative positions are listed in this report.
Mesa Laboratories President and CEO Siddhartha Kadia has filed a Form 3 insider report. The filing lists him as an officer but shows no reported purchases, sales, gifts, tax withholdings, or derivative transactions, indicating there are currently no insider trades or holdings disclosed in this report.
Long Path funds and affiliated managers amend a Schedule 13G to report ownership of 405,583 shares of Mesa Laboratories, Inc. Common Stock, equal to 7.3% of the class. Percentage is based on 5,524,813 shares outstanding as of January 31, 2026. The shares are directly held by Long Path Smaller Companies Fund, LP; the Reporting Persons disclaim beneficial ownership except to the extent of their pecuniary interest. This filing is Amendment No. 1 to the previously filed Schedule 13G.
Mesa Laboratories President and CEO Gary M. Owens reported the expiration and forfeiture of 8,211 restricted stock units, each representing one share of common stock. The RSUs were due to vest on June 15, 2028, but were deemed expired on March 31, 2026 and returned to the issuer rather than sold on the market. Following this disposition to the company, Owens holds 16,448 restricted stock units directly.
Mesa Laboratories Inc — Schedule 13G/A (Amendment No. 6) by The Vanguard Group. The filing states that The Vanguard Group reports zero shares beneficially owned of Mesa Laboratories common stock and 0% of the class. The amendment explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or divisions to report separately and disaggregated from The Vanguard Group, Inc. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Mesa Laboratories detailed the transition of President and CEO Gary Owens, whose departure was previously announced and will be effective on or about April 13, 2026. Under a new Retention and Transition Agreement dated March 20, 2026, he will continue in a non-executive role until June 22, 2026 to support an orderly handover.
At his June 22, 2026 separation, Mr. Owens will receive severance pay and benefits consistent with a “without cause” termination and keep a pro-rated portion of his June 15, 2025 performance stock unit award, vesting at the lower of target or actual performance. He must sign a release of claims to receive these benefits. He also resigned from the board as of March 20, 2026, and the company states his resignation was not due to any disagreement over operations, policies, or practices.
Mesa Laboratories (Common Stock) Schedule 13G: Long Path-related reporting persons report beneficial ownership of 311,703 shares, representing 5.6% of the class. Percentage ownership is based on 5,524,813 shares outstanding as of January 31, 2026.
The filing lists the owner as Long Path Smaller Companies Fund, LP with affiliated entities and two co-portfolio managers joining a joint filing. The shares are directly held by the Fund and the reporting parties disclaim beneficial ownership except for pecuniary interest.
Mesa Laboratories director Shiraz Shabanali Ladiwala reported an open-market purchase of 3,500 shares of Mesa Laboratories common stock at $72.23 per share. This buy on March 10, 2026 increased his directly held position to 8,523 shares, signaling a larger personal stake in the company.
Mesa Laboratories director Mark Christopher Capone bought additional company stock in an open-market transaction. He purchased 1,301 shares of Common Stock at a price of $76.35 per share. After this purchase, he directly owns 3,429 shares of Mesa Laboratories Common Stock.
Mesa Laboratories director R. Tony Tripeny bought shares of the company in the open market. He purchased 1,315 shares of Mesa Laboratories common stock at a price of $76.00 per share. After this transaction, his direct ownership increased to 5,398 common shares.